Literature DB >> 19682889

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.

O Matzinger1, F Duclos, A van den Bergh, C Carrie, S Villà, P Kitsios, P Poortmans, S Sundar, E M van der Steen-Banasik, A Gulyban, L Collette, M Bolla.   

Abstract

INTRODUCTION: This trial randomly assessed short-term adjuvant hormonal therapy added to radiotherapy (RT) for intermediate- and high-risk (UICC 1997 cT2a or cT1b-c with high PSA or Gleason score) localised prostate cancer. We report acute toxicity (CTCAE v2) assessed weekly during RT in relation to radiation parameters. PATIENTS AND METHODS: Centres selected the RT dose (70, 74 or 78Gy) and RT technique. Statistical significance is at 0.05.
RESULTS: Of 791 patients, 652 received 3D-CRT (70Gy: 195, 74Gy: 376, 78Gy: 81) and 139 received IMRT (74Gy: 28, 78Gy: 111). During RT, grade 3 gastrointestinal (GI) and genitourinary (GU) toxicities were reported by 7 (0.8%) and 50 (6.3%) patients, respectively. No grade 4 was reported. The risk of grade 2 GI toxicity increased significantly with increasing D50%-rectum (p=0.004) and that of grade 2 GU toxicity correlated only to Dmax-bladder (p=0.051). 3D-RT technique, increasing total dose and V95% >400 cc increased D50% and Dmax. One month after RT, only 14 patients (1.8%) reported grade 3 toxicity. AST did not seem to influence the risk of GU or GI acute toxicity.
CONCLUSION: RT up to 78Gy was well tolerated. Dmax-bladder and D50%-rectum influenced the risk of grade 2 GU toxicity and GI toxicity, respectively. Both were lower with IMRT but remained high for an irradiated RT volume>400 cc for 3D-RT and for a dose of 78Gy. Hormonal treatment did not influence acute toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682889     DOI: 10.1016/j.ejca.2009.07.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

1.  Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.

Authors:  Matthias Guckenberger; Sami Ok; Bülent Polat; Reinhart A Sweeney; Michael Flentje
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

2.  Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer: the DEGRO-QUIRO trial.

Authors:  L Keilholz; J Willner; H-J Thiel; N Zamboglou; H Sack; W Popp
Journal:  Strahlenther Onkol       Date:  2013-10-16       Impact factor: 3.621

3.  Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Authors:  Phillip M Pierorazio; Ashley E Ross; Brian M Lin; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin; Christian P Pavlovich; Edward M Schaeffer
Journal:  BJU Int       Date:  2012-02-28       Impact factor: 5.588

4.  High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer.

Authors:  Pirus Ghadjar; Nicole Gwerder; Peter Manser; Jacqueline Vock; Axel Madlung; Roberto Mini; Daniel M Aebersold
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

Review 5.  Gastrointestinal toxicity associated to radiation therapy.

Authors:  Mario López Rodríguez; Margarita Martín Martín; Laura Cerezo Padellano; Alicia Marín Palomo; Yamile Ibáñez Puebla
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.405

6.  Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer.

Authors:  Kentaro Ishii; Ryo Ogino; Yukinari Hosokawa; Chiaki Fujioka; Wataru Okada; Ryota Nakahara; Ryu Kawamorita; Takuhito Tada; Yoshiki Hayashi; Toshifumi Nakajima
Journal:  Br J Radiol       Date:  2016-03-31       Impact factor: 3.039

7.  [Radiotherapy in the treatment of advanced and recurrent prostate cancer].

Authors:  D Böhmer
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

Review 8.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

9.  Impact of bladder volume on acute genitourinary toxicity in intensity modulated radiotherapy for localized and locally advanced prostate cancer.

Authors:  Arne Grün; Michael Kawgan-Kagan; David Kaul; Harun Badakhshi; Carmen Stromberger; Volker Budach; Dirk Böhmer
Journal:  Strahlenther Onkol       Date:  2018-11-15       Impact factor: 3.621

10.  Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT.

Authors:  E Elif Ozkan; Alper Ozseven; Z Arda Kaymak Cerkesli
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.